We hypothesise that the TARS2 p.(Arg327Gln) variant results in neonatal diabetes by specifically disrupting TARS2's regulation of the mTORC1 pathway which in turn affects β‐cell survival and function. Here, TARS2 is linked to diabetes mellitus.